Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 9, 2007, Pages 3460-3465

  Kano, Mitsunobu R ^a,b   Bae, Younsoo ^b   Iwata, Caname ^a   Morishita, Yasuyuki ^a   Yashiro, Masakazu ^d   Oka, Masako ^a   Fujii, Tomoko ^a   Komuro, Akiyoshi ^a   Kiyono, Kunihiko ^a   Kaminishi, Michio ^a   Hirakawa, Kosei ^d   Ouchi, Yasuyoshi ^a   Nishiyama, Nobuhiro ^b,c   Kataoka, Kazunori ^b,c   Miyazono, Kohei ^a  

^a GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c University of Tokyo   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Gastric cancer; Molecular targeting therapy; Pancreatic cancer

Indexed keywords

DOXORUBICIN; LY 364947; NANOCARRIER; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR I INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CONTROLLED STUDY; DRUG TARGETING; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CANCER; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRROLES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 33847635618     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0611660104     Document Type: Article

References (36)

1. Muggia FM (2001) Curr Oncol Rep 3:156-162.
2. Ferrari M (2005) Nat Rev Cancer 5:161-171.
3. Hassan M, Little RF, Vogel A, Aleman K, Wyvill K, Yarchoan R, Gandjbakhche AH (2004) Technol Cancer Res Treat 3:451-457.
4. Emoto M, Udo T, Obama H, Eguchi F, Hachisuga T, Kawarabayashi T (1998) Gynecol Oncol 70:351-357.
5. Duncan R (2006) Nat Rev Cancer 6:688-701.
6. Kataoka K, Harada A, Nagasaki Y (2001) Adv Drug Deliv Rev 47:113-131.
7. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T (2005) Br J Cancer 92:1240-1246.
8. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K (2003) Cancer Res 63:8977-8983.
9. MacKenzie MJ (2004) Lancet Oncol 5:541-549.
10. Fuchs CS, Mayer RJ (1995) N Engl J Med 333:32-41.
11. Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. (1997) J Clin Oncol 15:2403-2413.
12. Watanabe N, Tsuji N, Tsuji Y, Sasaki H, Okamoto T, Akiyama S, Kobayashi D, Sato T, Yamauchi N, Niitsu Y (1996) Pancreas 13:395-400.
13. Matsumura Y, Maeda H (1986) Cancer Res 46:6387-6392.
14. Maeda H, Matsumura Y (1989) Crit Rev Ther Drug Carrier Syst 6:193-210.
15. Sofuni A, Iijima H, Moriyasu F, Nakayama D, Shimizu M, Nakamura K, Itokawa F, Itoi T (2005) J Gastroenterol 40:518-525.
16. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM (1996) Clin Cancer Res 2:1679-1684.
17. Roberts AB, Wakefield LM (2003) Proc Natl Acad Sci USA 100:8621-8623.
18. Feng XH, Derynck R (2005) Annu Rev Cell Dev Biol 21:659-693.
19. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, Mundy GR, Sun L-Z (2006) Cancer Res 66:6714-6721.
20. Yingling JM, Blanchard KL, Sawyer JS (2004) Nat Rev Drug Discov 3:1011-1022.
21. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, et al. (2003) J Med Chem 46:3953-3956.
22. Bae Y, Nishiyama N, Fukushima S, Koyama H, Matsumura Y, Kataoka K (2005) Bioconjug Chem 16:122-130.
23. Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K, Miyazawa K (2005) J Cell Sci 118:3759-3768.
24. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A (2006) J Natl Cancer Inst 98:335-344.
25. McDonald DM, Choyke PL (2003) Nat Med 9:713-725.
26. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT (2002) J Drug Target 10:539-548.
27. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M (1996) Clin Exp Metastasis 14:43-54.
28. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP (1999) Science 284:1534-1537.
29. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, Charlton R, Parums DV, Jowett T, Marchuk DA, et al. (2000) Dev Biol 217:42-53.
30. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, et al. (2000) Proc Natl Acad Sci USA 97:2626-2631.
31. Urness LD, Sorensen LK, Li DY (2000) Nat Genet 26:328-331.
32. Larsson J, Goumans MJ, Sjostrand LJ, van Rooijen MA, Ward D, Leveen P, Xu X, ten Dijke P, Mummery CL, Karlsson S (2001) EMBO J 20:1663-1673.
33. Watabe T, Nishihara A, Mishima K, Yamashita J, Shimizu K, Miyazawa K, Nishikawa S-I, Miyazono K (2003) J Cell Biol 163:1303-1311.
34. Hirschi KK, Rohovsky SA, D'Amore PA (1998) J Cell Biol 141:805-814.
35. Lebrin F, Deckers M, Bertolino P, ten Dijke P (2005) Cardiovasc Res 65:599-608.
36. Fernandez-L A, Sanz-Rodriguez F, Blanco FJ, Bernabeu C, Botella LM (2006) Clin Med Res 4:66-78.